SCHEMBL4628397

SCHEMBL4628397

Cc1ccc(C(=O)NC(=N)NCc2cccc3ccccc23)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN2A Q99250 2/20 0.60
SCN5A Q14524 1/20 0.60
CA2 P00918 1/20 0.54
F12 P00748 1/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
POLB P06746 2/20 0.49
NQO2 P16083 1/20 0.49
KDM4A O75164 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
MAPT P10636 2/20 0.48
HPGD P15428 2/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA4 P43681 1/20 0.47
LMNA P02545 3/20 0.46
PKM P14618 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4629004 0.86 NPC1 (0.55) CA2MEN1KMT2APOLBNQO2
SCHEMBL4629287 0.84 HPGD (0.55) CA2MEN1KMT2APOLBMAPT
SCHEMBL4628362 0.82 POLB (0.70) SCN2ASCN5AMEN1KMT2APOLB
SCHEMBL6702035 0.81 KMT2A (0.55) CA2MEN1KMT2ANQO2MAPT
SCHEMBL6702001 0.79 MTNR1A (0.59) CA2MEN1KMT2ANQO2MAPT
SCHEMBL4629282 0.77 RAB9A (0.58) SCN2ASCN5AMEN1KMT2APOLB
SCHEMBL6698279 0.77 KMT2A (0.51) CA2MEN1KMT2APOLBMAPT
SCHEMBL27876122 0.76 MTNR1A (0.49) CA2MEN1KMT2ANQO2MAPT
SCHEMBL3817884 0.76 CA2 (0.70) CA2MEN1KMT2AMAPTHPGD
SCHEMBL6570852 0.75 CA2 (0.69) CA2MEN1KMT2AMAPTCHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885SCN5A 1196/4885CA2 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.